Advances in Glioblastoma Therapy: An Update on Current Approaches
- PMID: 38002496
- PMCID: PMC10669378
- DOI: 10.3390/brainsci13111536
Advances in Glioblastoma Therapy: An Update on Current Approaches
Abstract
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high grade of malignancy and an extremely unfavorable prognosis. The current efficacy of established treatments for GBM is insufficient, necessitating the prompt development of novel therapeutic approaches. The progress made in the fundamental scientific understanding of GBM is swiftly translated into more advanced stages of therapeutic studies. Despite extensive efforts to identify new therapeutic approaches, GBM exhibits a high mortality rate. The current efficacy of treatments for GBM patients is insufficient due to factors such as tumor heterogeneity, the blood-brain barrier, glioma stem cells, drug efflux pumps, and DNA damage repair mechanisms. Considering this, pharmacological cocktail therapy has demonstrated a growing efficacy in addressing these challenges. Towards this, various forms of immunotherapy, including the immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy have emerged as potential strategies for enhancing the prognosis of GBM. Current investigations are focused on exploring combination therapies to mitigate undesirable side effects and enhance immune responses against tumors. Furthermore, clinical trials are underway to evaluate the efficacy of several strategies to circumvent the blood-brain barrier (BBB) to achieve targeted delivery in patients suffering from recurrent GBM. In this review, we have described the biological and molecular targets for GBM therapy, pharmacologic therapy status, prominent resistance mechanisms, and new treatment approaches. We also discuss these promising therapeutic approaches to assess prospective innovative therapeutic agents and evaluated the present state of preclinical and clinical studies in GBM treatment. Overall, this review attempts to provide comprehensive information on the current status of GBM therapy.
Keywords: glioblastoma multiforme; immunotherapy; nanocarriers; radiation; surgery; therapy; vaccines.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Emerging therapies for glioblastoma: current state and future directions.J Exp Clin Cancer Res. 2022 Apr 15;41(1):142. doi: 10.1186/s13046-022-02349-7. J Exp Clin Cancer Res. 2022. PMID: 35428347 Free PMC article. Review.
-
Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.Int Rev Immunol. 2022;41(6):582-605. doi: 10.1080/08830185.2022.2101647. Epub 2022 Aug 8. Int Rev Immunol. 2022. PMID: 35938932 Review.
-
Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.Cancer Med. 2021 Aug;10(15):5019-5030. doi: 10.1002/cam4.4064. Epub 2021 Jun 19. Cancer Med. 2021. PMID: 34145792 Free PMC article. Review.
-
Targeted therapies for Glioblastoma multiforme (GBM): State-of-the-art and future prospects.Drug Dev Res. 2024 Nov;85(7):e22261. doi: 10.1002/ddr.22261. Drug Dev Res. 2024. PMID: 39485272 Review.
-
Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.Adv Exp Med Biol. 2023;1394:73-84. doi: 10.1007/978-3-031-14732-6_5. Adv Exp Med Biol. 2023. PMID: 36587382
Cited by
-
CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review.Biomedicines. 2024 Jan 21;12(1):238. doi: 10.3390/biomedicines12010238. Biomedicines. 2024. PMID: 38275409 Free PMC article.
-
Thermal dose feedback control systems applied to magnetic nanoparticle hyperthermia.Int J Hyperthermia. 2025 Dec;42(1):2491519. doi: 10.1080/02656736.2025.2491519. Epub 2025 Apr 27. Int J Hyperthermia. 2025. PMID: 40289252
-
Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.Cancer Gene Ther. 2025 Jul;32(7):762-777. doi: 10.1038/s41417-025-00914-8. Epub 2025 May 21. Cancer Gene Ther. 2025. PMID: 40394233 Review.
-
The therapeutic potential of pegylated arginase I treatment in glioblastoma.Sci Rep. 2025 Aug 8;15(1):28994. doi: 10.1038/s41598-025-13882-8. Sci Rep. 2025. PMID: 40774999 Free PMC article.
-
LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular Models.Pharmaceutics. 2025 Feb 4;17(2):189. doi: 10.3390/pharmaceutics17020189. Pharmaceutics. 2025. PMID: 40006556 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources